Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Nov-Dec;31(6):1221-1223.
doi: 10.21873/invivo.11194.

Fibrotic Lung Toxicity Induced by Hydroxycarbamide

Affiliations
Case Reports

Fibrotic Lung Toxicity Induced by Hydroxycarbamide

Elena Bargagli et al. In Vivo. 2017 Nov-Dec.

Abstract

A patient treated for 4 months with hydroxycarbamide (hydroxyurea) for chronic myelomonocytic leukemia was admitted to hospital for recently developed severe dyspnea and acute respiratory failure. The computed tomographic scan of the chest showed diffuse ground glass opacities, some centrilobular low-density nodules (resembling hypersensitivity pneumonitis-like pattern), and minimal interstitial reticulation of the subpleural region. The analysis of bronchoalveolar lavage fluid excluded infection, as did serological examinations. The patient was started on oxygen therapy and with relief of thrombocytopenia and suspected hemolytic anemia, hydroxyurea treatment was discontinued. The patient underwent steroid therapy, with a rapid progressive improvement of clinical and radiological features. As hydroxyurea is increasingly used for a number of systemic disorders, physicians must be aware of its potential lung toxicity, requiring immediate cessation of the treatment and empiric corticosteroid therapy.

Keywords: Hydroxycarbamide; case report; hydroxyurea; interstitial pneumonitis; lung toxicity.

PubMed Disclaimer

Figures

Figure 1
Figure 1. High-resolution computed tomography of the chest showing diffuse ground-glass opacities (a), bilateral peripheral reticulations (b), areas of subpleural thickening (c), and bilateral centrilobular low-density nodules (d).

References

    1. Nevitt SJ, Jones AP, Howard J. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database Syst Rev. 2017;4:CD002202. - PMC - PubMed
    1. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332:1132–1136. - PubMed
    1. Grandi V, Delfino C, Pimpinelli N. Ingenol mebutate in the treatment of ‘hydroxyurea-induced squamous dysplasia’: a single-centre experience. J Eur Acad Dermatol Venereol. 2016;30(7):1129–1132. - PubMed
    1. Blanc PL, Joasson JM, Hammoud H, Matussière Y. Acute interstitial pneumopathy with fever caused by hydroxyurea. Presse Med. 2000;29(5):242–245. - PubMed
    1. Internullo M, Giannelli V, Sardo L, Antonaglia C, Villani T, Angelici E, Palange P. Hydroxyurea-induced interstitial pneumonitis: case report and review of the literature. Eur Rev Med Pharmacol Sci. 2014;18(2):190–193. - PubMed

Publication types

MeSH terms